Applied Immune Sciences Inc deal

AISX and strategic partner Rhone-Poulenc Rorer have revised the milestones under which AISX could require Rhone-Poulenc to acquire an additional 6 million shares of AISX worth about $130 million.

The 510(k) approvals originally were set as milestones for the Rhone-Poulenc investment. The new milestones include IND and IDE filings. ...